0:00
MICHAEL DEININGER: Hello,
I'm Michael Deininger.
I'm the chief of the
Division of Hematology
and Hematologic
Malignancies at the University
of Utah, Huntsman Cancer Institute.
Today, we're going to talk about
chronic myeloid leukemia, or CML,
genetic paradigm of targeted therapy.
The first part of the presentation
will focus on the biology of CML,
the Philadelphia chromosome, and
the development of Imatinib
as the first targeted agent
tyrosine kinase inhibitor for CML.
0:33
The story of chronic
myeloid leukemia, or CML,
starts in the middle
of the 19th century.
There were three eminent
physicians making major contributions.
Alfred Donné, in Paris, was probably
the first to recognize leukemia
also under the microscope.
John Bennet, in Edinburgh, was
the first to see a case of CML
and describe it.
Bennet thought that the case was
actually due to an infection,
because there was a 'separation
of the spleen', as he called it.
And just a few weeks later,
Rudolf Virchow, in Berlin,
described a similar case, but he
recognized the neoplastic nature
of the disease.
